- Case Report
- Open Access
Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension – clinical management
© Cottin; licensee BioMed Central Ltd. 2013
- Published: 16 April 2013
Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with a characteristic presentation of upper lobe emphysema and lower lobe fibrosis. While CPFE is a strong determinant of secondary precapillary pulmonary hypertension (PH), there is limited evidence regarding the management of patients with CPFE and PH.
A 63 year-old male presented in 2006 with dyspnoea on exertion having quit smoking in 2003. Clinical examination, together with high resolution computed tomography, bronchoalveolar lavage, and echocardiographic assessments, suggested a diagnosis of CPFE without PH. In 2007, the patient received intravenous cyclophosphamide, N-acetylcysteine, and short-term anticoagulation treatment. Due to remission of acute exacerbations, the patient received triple combination therapy (prednisone, N-acetylcysteine and azathioprine). Upon progressive clinical worsening, long-term supplemental oxygen therapy was initiated in 2009. Repeated right heart catheterisation in 2011 confirmed PH and worsening pulmonary haemodynamics, and off-label ambrisentan therapy was initiated. Dyspnoea remained at follow-up, although significant haemodynamic improvement was observed.
CFPE is a distinct but under-recognized and common syndrome with a characteristic presentation. Further studies are needed to ascertain the etiology, morbidity, and mortality of CPEF with or without PH, and to evaluate novel management options.
- Pulmonary Hypertension
- Idiopathic Pulmonary Fibrosis
- Pulmonary Fibrosis
- Interstitial Lung Disease
- Force Vital Capacity
There is an increasing awareness of comorbid conditions frequently associated with idiopathic pulmonary fibrosis (IPF), including emphysema, cardiovascular disease, thromboembolic disease, and obstructive sleep apnoea. Recent retrospective data suggest that 21 to 33% of patients with IPF may have co-existing emphysema [1–3]. The association of emphysema with IPF has been termed the combined pulmonary fibrosis and emphysema (CPFE) syndrome [4, 5] to account for the characteristic clinical, functional, imaging, and outcome features. Characteristics of patients with CPFE syndrome include male predominance, tobacco smoking, severe dyspnoea, subnormal spirometry findings, severely impaired transfer capacity for carbon monoxide [4, 6, 7], hypoxemia upon exercise, high frequency of paraseptal emphysema, and a high probability (30–50%) of severe pulmonary hypertension (PH) impacting upon an already poor prognosis [2, 4]. However, very limited evidence is available regarding the management of patients with PH in the CPFE syndrome.
A 63 year-old man presented in 2006 with dyspnoea on exertion (New York Heart Association (NYHA) functional class II). He had smoked 20 pack-years and quit smoking in 2003, had no professional exposure, and had a history of hypercholesterolemia treated with atorvastatin, and surgery for prostatic adenocarcinoma followed by complete remission. Clinical examination demonstrated fine ’Velcro‘-like crackles of the lung bases, with no finger clubbing, and the absence of clinical signs of connective tissue disease. The patient’s body mass index was 25 kg/m².
Treatment and patient management
In 2007, the patient presented with acute exacerbation of pulmonary fibrosis fulfilling international criteria , and BAL culture was negative; pulmonary embolism and left heart disease were excluded. The patient received intravenous cyclophosphamide (6-monthly pulses), N-acetylcysteine, and short-term anticoagulation treatment, but experienced clinical and HRCT remission of the acute exacerbation. He was further treated with triple combination therapy (prednisone, N-acetylcysteine 1.8 g per day, and azathioprine), with progressive clinical worsening despite therapy.
Right heart catheterisation in the patient with combined pulmonary fibrosis and emphysema.
PAP m (mmHg)
Cardiac index (L/min/m²)
Initiation of ambrisentan
In 2011, repeated catheterisation showed worsening of pulmonary haemodynamics, and off-label ambrisentan therapy (5 mg per day) was initiated, with no change in oxygen saturation and PaO2. At follow-up evaluation, dyspnoea was unchanged; however significant haemodynamic improvement was observed (Table 1), and 6-min walk distance improved by 27 m.
This patient case highlights a number of characteristics of the CPFE syndrome that contribute to distinctly different management compared with IPF alone (i.e. in the absence of emphysema). CPFE is a syndrome with characteristic presentation, including very low diffusion capacity contrasting with subnormal spirometry, occurring in heavy smokers with severe dyspnoea and exercise limitation. It may be overlooked due to subnormal lung volumes, however gas exchanges are severely altered. Despite moderate or severe emphysema, a large proportion of patients with CPFE have FEV1/FVC >70% indicating that GOLD criteria for chronic obstructive lung disease may not be applicable . In addition, diagnostic criteria of IPF may not apply, owing to difficulties in ascertaining honeycomb changes in patients with associated emphysema UIP  and a high frequency of mild-to-moderate ground glass opacities .
A limited amount of data is available regarding lung pathology in patients with CPFE. Indeed, severe alteration of gas exchange and emphysema features at imaging may explain why lung biopsy is rarely performed, as in this presented case. A variety of pathology patterns of pulmonary fibrosis have been reported in patients with CPFE, including predominantly UIP pattern , however nonspecific interstitial pneumonia , desquamative interstitial pneumonia (with extensive fibrosis), respiratory bronchiolitis, associated interstitial lung disease, airspace enlargement with fibrosis, or unclassifiable smoking-related interstitial fibrosis, may be observed.
This case further indicates that the natural course of disease in CPFE may encompass episodes of acute exacerbation of pulmonary fibrosis, a complication seldom reported previously in CPFE. Further, the presence of significant emphysema impacts FVC measurement, and thus changes in FVC alone may not be a reliable indicator of disease [7, 12]. Patients with CPFE should be excluded from IPF clinical trials . In fact, a decline in FEV1 by 10% or more at 6 or 12 months may be useful in assessing disease progression , which contrasts with the monitoring of IPF alone using serial changes in FVC and DLco. The main predictor of subsequent mortality is precapillary pulmonary hypertension [2, 4], which portends a dismal prognosis . Whether survival of patients with IPF is impacted by coexistent emphysema (e.g. CPFE) is controversial, due to difficulties in controlling for disease severity [2, 14]. A composite physiologic index may account for the extent of disease .
There are currently no specific recommendations for the treatment of pulmonary fibrosis, emphysema or PH in the setting of CPFE. It is unknown whether treating these components of disease influences clinical outcomes. Patients with CPFE are likely to require long-term oxygen therapy. The presented case indicates that therapy specific for pulmonary hypertension may improve haemodynamics, as in other isolated reports [13, 16], but the potential clinical and survival benefit is unknown. Results of a recent trial (‘ARTEMIS-IPF‘, NCT00768300) have showed that ambrisentan therapy is not beneficial and may even be deleterious in patients with IPF, regardless of associated PH, and should now be avoided in this condition. Treatment specific for PH may in some cases impair oxygenation by worsening ventilation/perfusion mismatch. Recent data have recommended against combination therapy with prednisone, azathioprine, and high-dose N-acetylcysteine in IPF management . Monotherapy using N-acetylcysteine is currently widely used in this setting, yet without evidence.
In conclusion, CPFE is a syndrome with characteristic presentation, and with a prognosis dominated by precapillary PH-associated with a poor prognosis, despite moderate haemodynamic severity. Further study is required regarding therapies targeting pulmonary fibrosis or PH.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Editorial assistance was provided by Irena Mandic, SH group Milan.
This article has been published as part of BMC Research Notes Volume 6 Supplement 1, 2013:IPF in 2011 – Key updates on guidelines and therapeutics. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcresnotes/supplements/6/S1. This supplement originates from presentations given at the symposium “AIR: Advancing IPF Research. Working together to translate IPF research into practice” held in Berlin in November 2011. The publication was supported by InterMed Communications with funding from InterMune, AG. The content was proposed by InterMed Communications and developed with the journal. All articles in the supplement have undergone the journal’s standard peer review process.
- Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM: Lone cryptogenic fibrosing alveolitis: A functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 1997, 155: 1367-1375. 10.1164/ajrccm.155.4.9105081.View ArticlePubMedGoogle Scholar
- Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, Barrientos E, Gaxiola M, Navarro C, Selman M: Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009, 136: 10-15. 10.1378/chest.08-2306.View ArticlePubMedGoogle Scholar
- Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR: Pulmonary function measures predict mortality differently in ipf versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011, 38: 176-183. 10.1183/09031936.00114010.PubMed CentralView ArticlePubMedGoogle Scholar
- Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF: Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur Respir J. 2005, 26: 586-593. 10.1183/09031936.05.00021005.View ArticlePubMedGoogle Scholar
- Cottin V, Cordier JF: The syndrome of combined pulmonary fibrosis and emphysema. Chest. 2009, 136: 1-2. 10.1378/chest.09-0538.View ArticlePubMedGoogle Scholar
- Wiggins J, Strickland B, Turner-Warwick M: Combined cryptogenic fibrosing alveolitis and emphysema: The value of high resolution computed tomography in assessment. Respir Med. 1990, 84: 365-369. 10.1016/S0954-6111(08)80070-4.View ArticlePubMedGoogle Scholar
- Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M: The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care. 2006, 51: 257-265.PubMedGoogle Scholar
- Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007, 176: 636-643. 10.1164/rccm.200703-463PP.PubMed CentralView ArticlePubMedGoogle Scholar
- Akira M, Inoue Y, Kitaichi M, Yamamoto S, Arai T, Toyokawa K: Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: Thin-section ct findings. Radiology. 2009, 251: 271-279. 10.1148/radiol.2511080917.View ArticlePubMedGoogle Scholar
- Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A: HRCT and histopathological evaluation of fibrosis and tissue destruction in ipf associated with pulmonary emphysema. Respir Med. 2008, 102: 1753-1761. 10.1016/j.rmed.2008.07.010.View ArticlePubMedGoogle Scholar
- Marten K, Milne D, Antoniou KM, Nicholson AG, Tennant RC, Hansel TT, Wells AU, Hansell DM: Non-specific interstitial pneumonia in cigarette smokers: A ct study. Eur Radiol. 2009Google Scholar
- Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, Watanabe K: Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med. 2009, 103: 1209-1215. 10.1016/j.rmed.2009.02.001.View ArticlePubMedGoogle Scholar
- Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF: Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010, 35: 105-111. 10.1183/09031936.00038709.View ArticlePubMedGoogle Scholar
- Todd NW, Jeudy J, Lavania S, Franks TJ, Galvin JR, Deepak J, Britt EJ, Atamas SP: Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair. 2011, 4: 6-10.1186/1755-1536-4-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM: Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003, 167: 962-969. 10.1164/rccm.2111053.View ArticlePubMedGoogle Scholar
- Mercurio V, Carlomagno G, Fazio S: Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature. Heart Lung. 2012Google Scholar
- Wells AU, Behr J, Costabel U, Cottin V, Poletti V: “Triple therapy” in idiopathic pulmonary fibrosis: An alarming press release?. Eur Respir J. 2012, 39: 805-806. 10.1183/09031936.00009112.View ArticlePubMedGoogle Scholar